P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY

por Kuruvilla, J., Armand, P., Herrera, A. F., Ribrag, V., Brice, P., Thieblemont, C., Von Tresckow, B., Kim, E., Marinello, P., Chakraborty, S., Orlowski, R., Zinzani, P. L.
Publicado 2022

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LAB...

por Herrera, A. F., Lavie, D., Johnson, N. A., Avigdor, A., Borchmann, P., Andreadis, C., Bazargan, A., Gregory, G., Keane, C., Inna, T., Vucinic, V., Zinzani, P. L., Zhang, H., Pillai, P., Marinello, P., Timmerman, J.
Publicado 2022

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY...

por Gregory, G., Timmerman, J., Lavie, D., Borchmann, P., Herrera, A. F., Minuk, L., Vucinic, V., Armand, P., Avigdor, A., Gasiorowski, R., Herishanu, Y., Keane, C., Kuruvilla, J., Palcza, J., Pillai, P., Marinello, P., Johnson, N. A.
Publicado 2022

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL

por Morschhauser, F., Jiang, Y., Jardin, F., Herrera, A. F., Sehn, L. H., Herbaux, C., Flowers, C., Phillips, T., López Guillermo, A., Diefenbach, C., Gregory, G. P., Kim, A., Barbui, A. M., Balasubramanian, S., Harris, W., Hirata, J., Paulson, J. N., Lee, C., Lenz, G.
Publicado 2022